Autoinjector preference among patients with multiple sclerosis: results from a national survey

Autoinjector preference among patients with multiple sclerosis: results from a national survey

V Limmroth,1 J Reischl,2 B Mann,3 X Morosov,2 A Kokoschka,2 I Weller,2 T Schreiner2 1Clinic for Neurology and Palliative Medicine, Municipal Hospital Köln-Merheim, Cologne, 2Bayer Vital GmbH, Leverkusen, 3IFAK Institute GmbH & Co. KG, Taunusstein, Germany Purpose: Autoinjectors ar...

Full description

Bibliographic Details
Main Authors:	Limmroth V, Reischl J, Mann B, Morosov X, Kokoschka A, Weller I, Schreiner T
Format:	Article
Language:	English
Published:	Dove Medical Press 2017-08-01
Series:	Patient Preference and Adherence
Subjects:	adherence multiple sclerosis immunomodulatory therapy electronic autoinjector market survey
Online Access:	https://www.dovepress.com/autoinjector-preference-among-patients-with-multiple-sclerosis-results-peer-reviewed-article-PPA

Similar Items

Predictors of Adherence Among Patients With Multiple Sclerosis Using the BETACONNECT® Autoinjector: A Prospective Observational Cohort Study
by: Wolfgang Köhler, et al.
Published: (2021-02-01)

Adherence with epinephrine autoinjector prescriptions in primary care
by: Elissa M. Abrams, et al.
Published: (2017-11-01)

Adherence, satisfaction and functional health status among patients with multiple sclerosis using the BETACONNECT® autoinjector: a prospective observational cohort study
by: Ingo Kleiter, et al.
Published: (2017-09-01)

Potential Benefits of the Self-Administration of Subcutaneous Methotrexate with Autoinjector Devices for Patients: A Review
by: Tornero Molina J, et al.
Published: (2021-03-01)

Improving adrenaline autoinjector adherence: A psychologically informed training for healthcare professionals
by: Béré Mahoney, et al.
Published: (2019-09-01)

Autoinjectors Preferred for Intramuscular Epinephrine in Anaphylaxis and Allergic Reactions
by: Ronna L Campbell, et al.
Published: (2016-11-01)

The pharmacokinetics of epinephrine/adrenaline autoinjectors
by: Sten Dreborg, et al.
Published: (2021-03-01)

Nurse and Patient Perceptions and Preferences for Subcutaneous Autoinjectors for Inflammatory Joint or Bowel Disease: Findings from a European Survey
by: Steve Fenwick, et al.
Published: (2019-02-01)

BetaEval Global: Prospective, Multinational, Observational Cohort Study of Patients Using BETACONNECT®
by: Patti F, et al.
Published: (2020-04-01)

EAACI Task force Clinical epidemiology of anaphylaxis: experts’ perspective on the use of adrenaline autoinjectors in Europe
by: Magdalena Kraft, et al.
Published: (2020-05-01)

Usability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported experience
by: Callis Duffin K, et al.
Published: (2016-10-01)

Human factors validation study of 3 mg sumatriptan autoinjector, for migraine patients
by: Brand-Schieber E, et al.
Published: (2016-05-01)

Subjective patient-reported versus objective adherence to subcutaneous interferon β-1a in multiple sclerosis using RebiSmart®: the CORE study
by: Chiara Zecca, et al.
Published: (2017-09-01)

Comparison of the Pharmacokinetics, Safety, and Tolerability of the Autoinjector (AI) and Pre-Filled Syringe (PFS) of SB4 in Healthy Subjects
by: Shin D, et al.
Published: (2020-01-01)

Single-Use Autoinjector Functionality And Reliability For At-Home Administration Of Benralizumab For Patients With Severe Asthma: GRECO Trial Results
by: Ferguson GT, et al.
Published: (2019-10-01)

Patient Reported Ease-of-Use with a Disposable Autoinjector in Individuals with Migraine
by: Mead J, et al.
Published: (2020-07-01)

Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)
by: Peter Nash, et al.
Published: (2018-03-01)

Dynamics of quality of life indicators at a multiple sclerosis
by: V. N. Karnaukh, et al.
Published: (2010-08-01)

The use of immunomodulatory therapy in pregnant patients with multiple sclerosis
by: Julia Rudnicka-Czerwiec, et al.
Published: (2018-11-01)

Epinephrine autoinjector prescription patterns for severe anaphylactic patients in Japan: A retrospective analysis of health insurance claims data
by: Mikio Nakajima, et al.
Published: (2020-07-01)

Multiple sclerosis and COVID-19
by: Jan Mares, et al.
Published: (2020-09-01)

Functionality and Performance of an Accessorized Pre-Filled Syringe and an Autoinjector for At-Home Administration of Tezepelumab in Patients with Severe, Uncontrolled Asthma
by: Alpizar S, et al.
Published: (2021-04-01)

A case report of late‐onset atypical Hemolytic Uremic Syndrome during interferon beta in multiple sclerosis: Open issues in literature review
by: Mosè Parisi, et al.
Published: (2021-01-01)

Economic burden of multiple sclerosis
by: Uroš Rot, et al.
Published: (2014-08-01)

Immunomodulatory and Anti-Inflammatory Effects of Scrophularia megalantha Ethanol Extract on an Experimental Model of Multiple Sclerosis
by: Abbas Azadmehr*, et al.
Published: (2018-01-01)

Pharmacokinetic Profile of Subcutaneous Testosterone Enanthate Delivered via a Novel, Prefilled Single‐Use Autoinjector: A Phase II Study
by: Jed Kaminetsky, MD, et al.
Published: (2015-12-01)

Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
by: Özlem Taşkapılıoğlu, et al.
Published: (2012-03-01)

Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
by: Özlem Taşkapılıoğlu, et al.
Published: (2012-03-01)

The Danish Multiple Sclerosis Treatment Register
by: Magyari M, et al.
Published: (2016-10-01)

User-Centric Approach to Specifying Technical Attributes of Drug Delivery Devices: Empirical Study of Autoinjector-Cap Removal Forces
by: Schneider A, et al.
Published: (2021-02-01)

Use of monoclonal antibodies in patients with multiple sclerosis in the practice of a neurologist
by: N. Yu. Lashch
Published: (2020-03-01)

Subcutaneous sumatriptan delivery devices: comparative ease of use and preference among migraineurs
by: Andre AD, et al.
Published: (2017-01-01)

Non-adherence to Disease-Modifying Treatments in Patients with Multiple Sclerosis
by: Seyed-Ali Roudbary, et al.
Published: (2017-08-01)

Monoclonal antibodies in the treatment of multiple sclerosis: from clinical research to practical application
by: N. Yu. Lashch
Published: (2020-07-01)

Longitudinal Serum Neurofilament Levels of Multiple Sclerosis Patients Before and After Treatment with First-Line Immunomodulatory Therapies
by: André Huss, et al.
Published: (2020-08-01)

Adherence to disease-modifying therapies in patients with multiple sclerosis
by: Kołtuniuk A, et al.
Published: (2018-08-01)

Relevance of first-line drugs for treatment of multiple sclerosis in present-day conditions
by: N. Yu. Lashch
Published: (2020-12-01)

Conversion to Secondary Progressive Multiple Sclerosis: Patient Awareness and Needs. Results From an Online Survey in Italy and Germany
by: Alessandra Solari, et al.
Published: (2019-08-01)

Recomendações quanto ao uso de drogas imunomoduladoras na esclerose múltipla: o consenso do BCTRIMS Recommendations for the use of immunomodulatory drugs in multiple sclerosis: the BCTRIMS consensus
by: CHARLES PETER TILBERY, et al.
Published: (2000-09-01)

Pharmacoeconomic aspects of poor adherence to treatment in multiple sclerosis management
by: Mario Eandi
Published: (2011-09-01)

Cannot write session to /tmp/vufind_sessions/sess_bus6gn94i4eosocnahafjmt1q4